Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma

References

• Coleman M, Leonard J, Shuster MW, . DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL). Eur J Haematol Suppl 2001;64:41–45.
   PubMedGoogle Scholar
• Moskowitz CH, Bertino JR, Glassman JR, . Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3776–3785.
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Nimer SD, . Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684–3688.
   PubMed Web of Science ®Google Scholar
• Philip T, Chauvin F, Armitage J, . Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 1991;77: 1587–1592.
   PubMed Web of Science ®Google Scholar
• Velasquez WS, McLaughlin P, Tucker S, . ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169–1176.
   PubMed Web of Science ®Google Scholar
• Girouard C, Dufresne J, Imrie K, . Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol 1997;8:675–680.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, . Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184–4190.
   PubMed Web of Science ®Google Scholar
• Gianni AM, Bregni M, Siena S, . High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290–1297.
   PubMed Web of Science ®Google Scholar
• Vose JM, Zhang MJ, Rowlings PA, . Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19:406–413.
   PubMed Web of Science ®Google Scholar
• Moskowitz C. Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy. Cancer Chemother Pharmacol 2002;49(Suppl. 1):S9–S12.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Richardson PG, . The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377–2380.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Janik J, Gea-Banacloche J, . Phase I/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma. Blood 2004;104(Suppl. 1): Abstract 1385.
   Google Scholar
• Dunleavy K, Pittaluga S, Czuczman MS, . Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069–6076.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Furman RR, . Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690–697.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275–282.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1–10.
   PubMedGoogle Scholar
• Hoppe BS, Moskowitz CH, Zhang Z, . The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplant 2009;43:941–948.
   PubMed Web of Science ®Google Scholar
• Derenzini E, Musuraca G, Fanti S, . Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer 2008;113:2496–2503.
   PubMed Web of Science ®Google Scholar
• Dickinson M, Hoyt R, Roberts AW, . Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol 2010;150:39–45.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chauhan D, . The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071–3076.
   PubMed Web of Science ®Google Scholar
• Bernal-Mizrachi L, Lovly CM, Ratner L. The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc Natl Acad Sci USA 2006;103:9220–9225.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Zelenetz AD, Kewalramani T, . Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 2005;106:3383–3385.
   PubMed Web of Science ®Google Scholar
• Shah SA, Potter MW, McDade TP, . 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001;82:110–122.
   PubMed Web of Science ®Google Scholar
• Perez-Galan P, Roue G, Villamor N, . The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006;107:257–264.
   PubMed Web of Science ®Google Scholar
• Strauss SJ, Higginbottom K, Juliger S, . The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res 2007;67:2783–2790.
   PubMed Web of Science ®Google Scholar
• Gu H, Chen X, Gao G, . Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Mol Cancer Ther 2008;7: 2298–2307.
   PubMed Web of Science ®Google Scholar
• Al-Tourah AJ, Gill KK, Chhanabhai M, . Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5165–5169.
   PubMed Web of Science ®Google Scholar
• Williams CD, Harrison CN, Lister TA, . High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 2001;19:727–735.
   PubMed Web of Science ®Google Scholar